New Update on Actos Lawsuits Alleging Bladder Cancer; Resource4thePeople Reports New Multidistrict Hearing Scheduled and Medication Banned in India
National network of attorneys continues to offer free consultations to consumers seeking compensation over allegations that use of diabetes drug can lead to bladder cancer as more lawsuits filed.
San Diego, CA (PRWEB) July 13, 2013
Resource4thePeople announced today its latest consumer update about litigation and other developments involving allegations that the use of the diabetes drug Actos (pioglitazone) may cause patients to develop bladder cancer.
The most important development is that a status conference has been scheduled for July 25, 2013 in the multidistrict litigation involving over 1,300 Actos lawsuits that have been filed across the country.*
The hearing was scheduled by U.S. District Judge Rebecca F. Doherty in the Western District of Louisiana. Doherty was chosen by a national federal panel of judges to oversee pre-trial evidence-gathering and legal procedures in the litigation and possibly eventually decide whether to grant the litigation class-action status.
“We are encouraged that the judge is actively managing these hundreds of lawsuits which allege that the long-term use of Actos to treat their diabetes may expose them to life-threatening injuries,” said Resource4thePeople.
“We will continue to monitor these proceedings and report the status of the litigation to consumers who may have been affected by the alleged side effects that are central to these lawsuits.”
Resource4thePeople also announced that its nationwide network of attorneys will continue to offer free consultations to consumers who may be seeking information about their legal rights to seek compensation over similar allegations.
“Dependent upon the circumstances of each individual case, the fact that this multidistrict litigation is moving forward does not compromise the rights of any other consumer to seek legal information and possibly file their own claim or lawsuit involving Actos bladder cancer allegations,” said Resource4thePeople.
The court file in the Louisiana multidistrict litigation does not provide details what will be discussed at the status hearing, noting that “the agenda is being prepared.”
However, the court file shows from minutes of past status conferences that among the topics usually discussed are developments in evidence-gathering, details of new state and federal court Actos lawsuits and other pre-trial developments.
Resource4thePeople also is reporting another important development in connection with allegations that Actos may be linked to life-threatening bladder cancer: India has now banned the sale of the medication out of concerns for consumer safety.
The ban on Actos, manufactured by Asian pharmaceutical giant Takeda Pharmaceuticals, was reported** in the June 27, 2013 edition of The Times of India, the national newspaper, which wrote:
“In the case of pioglitazone too, France has already taken it off the shelves, while in the US it is sold with a boxed warning. The warning emphasizes that it may cause or worsen heart failure, and its use for over a year may be associated with an increased risk of bladder cancer.”
The Times report said that the government also banned sales of the pain-killer analgin and anti-depressant deanxit “in the wake of health risks associated with them.”
The Times said the ministry of health and family welfare has suspended the manufacture and sale of all three drugs under Section 26A of the Drugs and Cosmetics Act, 1940 with immediate effect, through a notification issued on June 18.
“While the ministry has been dilly-dallying on withdrawing analgin and deanxit for years now, despite pressure from a parliamentary panel, the decision on the diabetes drug pioglitazone has taken the industry completely by surprise,” said the Times.
Concerns about Actos were raised by the U.S. Food and Drug Administration on June 15, 2011 after the agency staff reviewed a Takeda-sponsored study which documented an increased risk of developing bladder cancer with Actos than other diabetes drugs.***
Here is part of the safety announcement:
“The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.”
Resource4thePeople is also responding to consumer inquiries by making them aware that Actos also has been banned in Germany but has not been recalled so far in the United States, where the FDA has chosen to issue a health warning.
Meanwhile, lawsuits continue to be filed over allegations that the use of Actos caused bladder cancer. Among the most recent:
- A man who is alleging that the was diagnosed with bladder cancer after taking Actos for 10 years to treat his diabetes filed an Actos bladder cancer lawsuit in Louisiana June 12, 2013.****
- A man who claims he developed cancer after taking Actos for five years has filed an Actos bladder cancer suit May 23, 2013 in Louisiana.*****
- A woman who is claiming that her father died of bladder cancer as a result of his long-term use of Actos to treat diabetes has filed an Actos lawsuit June 10, 2013 in New Jersey.******
"The filing of these lawsuits shows that patients and their loved ones are continuing to come forward with similar allegation in which they are alleging that Actos has life-threatening side effects that were not adequately made public to consumers and physicians," said Resource4thePeople.
*In Re: Actos (Pioglitazone) Products Liability Litigation, MDL2299 U.S. District Court, Western District of Louisiana
**** Case # 6:2013cv01630, U.S. District Court, Western District of Louisiana
*****Case # 6:13cv1235, U.S. District Court for the Western District of Louisiana
******Case # 2:13cv3602, U.S. District Court for the District of New Jersey
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10921641.htm